Tag Archive for: oncology

STORM Therapeutics to Present Phase 1 Data on its First-in-Class Lead Product STC-15 at EORTC-NCI-AACR Symposium

/in

STC-15 is the first METTL3 inhibitor to enter clinical development Presentation to highlight updated interim results, demonstrating that STC-15 was well tolerated, and clinical activity observed across pharmacologically active dose range in advanced cancer patients 9 October 2024, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat […]

Read more

Curve Therapeutics continues to enhance leadership team with appointment of Rab Prinjha as Chief R&D Officer

/in

Deep expertise in leading drug discovery programs across oncology, neuroscience and epigenetics Will drive advancement of Curve’s rich pipeline of first-in-class therapeutic assets Builds on recent leadership team appointments, including Andre Hoekema as Chair of the Board Southampton, UK, 9 October 2024 – Curve Therapeutics (“Curve” or the “Company”), a private biotechnology company pioneering a […]

Read more

Adcendo Announces US FDA Clearance of IND Application for Phase I/II First-in-Human ADCElerate-01 Trial of ADCE-D01 (uPARAP Receptor Targeting ADC) Trial in Patients with Metastatic and/or Unresectable Soft Tissue Sarcoma (STS)

/in

ADCE-D01 is a first-in-class antibody-drug conjugate (ADC) targeting uPARAP, an endocytic receptor which is highly overexpressed in mesenchymal cancers including multiple STS subtypes The Phase I/II ADCElerate-01 trial is designed to evaluate the safety, pharmacokinetics, and preliminary efficacy of ADCE-D01 as a monotherapy in patients with metastatic and/or unresectable STS Copenhagen, Denmark, October 8th, 2024 – […]

Read more

Curve Therapeutics further strengthens leadership team with the appointment of Andre Hoekema as new Chair of Board

/in

Dr Hoekema brings over four decades of successful biotech and life science leadership Dr Cora Griffin appointed to head up business development, follows recent appointment of Simon Jones as CFO/COO New hires to accelerate ambition to turbocharge the discovery platform, develop innovative therapeutic pipeline and expand pharma relationships Southampton, UK, 2 October 2024 – Curve […]

Read more

Poolbeg Pharma plc – Interim results for the six months to 30 June 2024

/in

Lead development candidate (POLB 001) on track with positive data demonstrating efficacy Independent research endorses potential US$10bn market opportunity for POLB 001 in cancer immunotherapy-induced CRS Patent portfolio significantly strengthened & expanded Continued focus on high value programmes & partnerships to develop & commercialise assets Strong Balance Sheet – cash balance of £10.1m Experienced leadership team with track […]

Read more